Department of Dermatology, Goethe-University, Frankfurt am Main, Germany.
G Ital Dermatol Venereol. 2009 Dec;144(6):701-11.
Psoriasis, a chronic common immune-mediated disease with frequent remitting/relapsing courses, has a high negative impact on the quality of life, especially in patients moderately or severely affected by the disease. It is also associated with various co-morbidities resulting in a decreased life expectancy and remarkable socioeconomic costs. At least one third of the patients who suffer from it has moderate or severe psoriasis and require continuous treatment to control disease activity. The therapeutic approach in daily practice is usually determined by the severity of the disease. Whether the definition of disease severity is not always clear, there is a considerable number of patients requiring systemic treatment to control the symptoms of psoriasis. The treatment options available for the management of moderate-severe psoriasis have dramatically increased over the past decade, and now range from phototherapy to traditional systemic treatments to biologics. Available data from clinical trials and growing number of patients treated with biologics shows that this new agent are effective and relatively safe to control psoriasis, and are coupled with improved tolerability, convenience and improvement in quality of life. This review shortly presents the characteristics, safety and efficacy profile of the conventional and newer systemic drugs used in moderate-to-severe psoriasis.
银屑病，一种慢性常见的免疫介导性疾病，常有缓解/复发过程，对生活质量有很大的负面影响，尤其是对疾病中重度影响的患者。它还与各种合并症相关，导致预期寿命缩短和显著的社会经济成本。至少三分之一患有中度或重度银屑病的患者需要持续治疗来控制疾病活动。在日常实践中，治疗方法通常取决于疾病的严重程度。尽管疾病严重程度的定义并不总是明确的，但仍有相当数量的患者需要系统治疗来控制银屑病的症状。过去十年中，中度至重度银屑病的管理治疗选择显著增加，现在包括光疗、传统系统治疗到生物制剂。来自临床试验的现有数据和越来越多接受生物制剂治疗的患者表明，这些新药物在控制银屑病方面有效且相对安全，并具有改善的耐受性、便利性和生活质量的提高。本文简要介绍了中重度银屑病中使用的传统和新型系统药物的特点、安全性和疗效概况。
